XL765 Chemical Structure
BEZ235 (NVP-BEZ235)is a dual ATP-competitive phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM,respectively.
Deforolimus (Ridaforolimus) is a small-molecule inhibitor of mTOR.
Perifosine is an Akt inhibitor. the antiproliferative properties of perifosine with an IC50 of 0.6–8.9 µM.
PI-103 is a potent, cell-permeable, ATP-competitive PI3K family member inhibitor with IC50 of 2, 8, 20, 26, 48, 83, 88, 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γ, respectively.
Rapamycin also known as Sirolimus & Rapamune is an mTOR inhibitor. Rapamycin Sirolimus inhibits cell motility by suppression of mTOR-mediated pathways.
Temsirolimus (Torisel) is a mTOR inhibitor.
Inhibitor of Class I PI3 Kinase,p110a IC50=0.003uM,U87MG IC50=0.95μM.
ZSTK474 is an inhibitor of PI3K γ(IC50 at 6 nM).
LY294002 is a PI3k inhibitor (cell IC50 about 10 μM) and a casein kinase II inhibitor.
XL147 is a selective inhibitor of Class I PI3K isoforms.
XL765 is a mixed mTOR/PI3k inhibitor with IC50 of 157, 39, 113, 9 and 43 nM for mTOR, p110α, β, γ and δ, respectively. It is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). In preclinical studies, XL765 slowed tumor growth or caused tumor shrinkage in multiple preclinical cancer models, including breast, lung, ovarian, and prostate cancers, and gliomas. XL765 has also been shown to enhance the anti-tumor effects of several chemotherapeutic agents in preclinical cancer models. [1]
| Molecular Weight (WM): | 599.66 |
|---|---|
| Formula: | C31H29N5O6S |
| CAS No.: | 1349796-36-6 |
| Synonyms: |
N/A
|
| Dissolve in (25°C): | DMSO ≥15mg/mL |
| Water <1mg/mL | |
| Ethanol <1mg/mL | |
| Storage: | 2 years-20°CPowder |
| 1 week-4°Cin DMSO | |
| 1 month-80°in DMSO |
A collection of 864 bioactive compounds
A collection of 481 inhibitors
A collection of 194 kinase inhibitors
A collection of 85 tyrosine kinase inhibitors.
A collection of 426 FDA approved drugs
A collection of 139 natural products
A collection of 40 chemotherapeutic agents
A unique collection of 17 small molecule modulators
A unique collection of 47 small molecule inhibitors
A unique collection of 63 GPCR small molecules

After starved in serum-free medium for 24h,A549 cells incubated with the indicated concentrations of XL765 for 3h,followed by 20-minute stimolation of 100ng/ml EGF. |
After starved in serum-free medium for 24h,A549 cells incubated with the indicated concentrations of XL765 for 3h,followed by 20-minute stimolation of 100ng/ml EGF.
Data independently produced by Dr. Zhang of Tianjin Medical University XL765 purchased from Selleck
Keywords:buy XL765 | XL765 supplier | purchase XL765 | XL765 cost | XL765 manufacturer | order XL765 | XL765 distributor